Why the study?
Does intravenous sotalol alter electrophysiological parameters in patients undergoing routine electrophysiological study?
Does intravenous sotalol alter electrophysiological parameters in patients undergoing routine electrophysiological study?
Intravenous sotalol prolongs atrial, ventricular, and accessory pathway refractory periods as well as ventricular repolarization, demonstrating Class III antiarrhythmic properties beyond typical beta-blockade.
No takes yet. Share an insight, caveat, or question.
May support adjunctive sotalol in select EP-lab AVRT cases; leaves open broader adoption pending randomized data.
Nathan et al. (1982) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: